Health Conditions Medical Marijuana Can Treat

Throughout the early decades of the 21st century, the use of medical marijuana has been increasingly explored and recognized to treat a range of problems that are ineffectively treated with other drugs and therapies.

A sad woman sitting on the stairs
portishead1 / istockphoto

The support of physicians and patients who have found medical marijuana to be effective in helping with symptoms of these conditions has led some jurisdictions to allow the use of medical marijuana for a recognized condition if prescribed by a doctor.

Derivatives of marijuana and synthetic marijuana—which aims to give the same medical benefits without the drug hig—are also being developed and, in some cases, used as forms of medical marijuana. One of these synthetic forms of medical marijuana is Marinol.

What It Can Treat

Over 200 separate indications or uses for medical cannabis have been identified. These can be broken down into the following broad categories:

  • Anti-nauseant and appetite stimulant
  • Anti-spasmodic and anti-convulsant
  • Analgesic (pain reliever)
  • Anti-inflammatory and immune system modulator
  • Anxiolytic (anxiety reliever) and antidepressant for mood disorders
  • Harm reduction substitute for alcohol, opiates, and other dangerous drugs

Although it is important to note that the U.S. Food and Drug Administration (FDA) has not approved marijuana for any medical indication, medical marijuana is still sometimes prescribed for certain conditions including, but not limited to:

Harmful Effects 

Several potentially harmful effects of medical marijuana have been identified.

These include cardiovascular issues associated with marijuana use such as heartbeat and blood pressure implications. Additionally, cannabis use may result in an increased risk of injury in older adults, as well as a higher risk of developing severe mental illness, especially with frequent use.

Those with existing heart problems may be especially affected by the increase in heart rate (tachycardia) caused by marijuana intoxication, but even those without a preexisting condition should only use marijuana after discussing the risks and benefits with their prescribing physician.

Marijuana occasionally causes faintness when users stand up abruptly, a condition known as postural hypotension. This poses a risk of passing out, falling, and possibly suffering a potentially fatal injury. The effects of marijuana on blood pressure are unpredictable, so any concerns should be discussed with your prescribing physician.

Pregnancy

There is no known safe level of cannabis exposure during pregnancy and lactation.

Research on the effects of prenatal exposure to marijuana on children at various stages of development shows a potential increased risk of low birthweight. Other studies indicate possible serious neurological effects on the developing child.

However, these studies, as well as those reflecting the consequences of prenatal marijuana exposure at later stages of development, may be confounded or confused by the fact that women who use marijuana during pregnancy are more likely to engage in other behaviors that put a baby at risk, such as tobacco smoking or using other recreational drugs.

Overall, doctors have expressed concern about the safety of marijuana during pregnancy. Marijuana is fat-soluble, and it easily crosses the placenta and blood-brain barrier. Therefore, if a mother uses marijuana, it can accumulate in the tissues and brain of her baby. It has the potential to disrupt motor control, memory, and other brain functions.

There is a significantly increased risk for anencephaly—a serious birth defect in which a baby is born without parts of the brain and skull—when the fetus is exposed to marijuana during the first month of gestation (one to four weeks after conception).

There is also some evidence that marijuana use during pregnancy can impair structural brain development in the fetus, as well as affect the neurotransmitters that play a role in cognitive and emotional functioning.

Developmental Issues

Numerous studies have documented neurodevelopmental deficits in older children, adolescents, and young adults who were prenatally exposed to marijuana. These studies are consistent with the effects of cannabis on the developing fetal central nervous system.

Children who had been prenatally exposed to marijuana and were followed up over time were found to have a consistent pattern of deficits in cognitive functioning. At 6 years of age, prenatal marijuana exposure was linked to lower verbal reasoning scores and deficits in composite, short-term memory, and quantitative intelligence scores. By the time they were 10 years of age, negative effects of prenatal marijuana exposure had a significant impact on design memory and assessments of learning and memory, and the exposed children had lower test scores on school achievement.

They were also more likely to have increased hyperactivity, impulsivity, and inattention problems as well as significantly increased rates of child depressive symptoms. These symptoms significantly predicted delinquency at 14 years and a significantly increased rate of difficulties with executive functioning, which is central to learning and managing behavior. Young adults who had been prenatally exposed to marijuana have been found to have altered neural functioning that impacted short-term memory.

As stated above, these research findings are complicated by the tendency of children of mothers who use marijuana during pregnancy to have been exposed to other substances, stressors, and other problems. However, until more conclusive research is available, marijuana is best avoided during pregnancy and breastfeeding.

Adverse Reactions 

Several adverse reactions to marijuana have been reported, including racing heartbeat, faintness, twitches, numbness, and headaches. Lower frequency of use may increase the frequency of adverse reactions.

Although rare, true allergies to marijuana can occur and range from rashes and itchiness to full flown anaphylaxis.

If you experience any symptoms that you think may be allergy related, discontinue use and discuss with your prescribing physician.

What Is Marinol?

Marinol is a form of medical marijuana. It is a synthetic version of the delta-9-THC compound, which occurs naturally in the cannabis plant.

Marinol is prescribed as an appetite stimulant for people who have severe symptoms of appetite loss, nausea and vomiting, caused by conditions such as AIDS and cancer, as well as related treatment.

Medical marijuana is controversial because recreational marijuana has been a controlled drug for many years. For this reason, Marinol is only prescribed to people who have severe conditions and who have not responded adequately to other treatments for their symptoms.

Marinol Effects and Side Effects

People who take Marinol may experience some of the pleasurable effects of regular recreational marijuana, including elation and euphoria.

Marinol can have some unpleasant side effects, including paranoia and hallucinations, upset stomach, and drowsiness.

Is Medical Marijuana Just Another Way to Abuse Drugs?

The terms "drug abuse" and "substance abuse" are inherently judgmental and imply blame of the person using the substances rather than the substances themselves. Therefore, the use of these terms is falling out of favor with professionals.

However, the question of whether the current medical marijuana system is being used as intended does raise some interesting findings.

Research reported in 2017 indicates that marijuana users who are not medical marijuana patients report using marijuana diverted from dispensaries. Such marijuana users are more likely to use prescription drugs not prescribed to them than those who are prescribed marijuana.

This indicates that recreational users are turning to illicit, diverted, prescribed sources of substances, rather than traditional street drugs, adding medical marijuana to the list of prescribed drugs being diverted for recreational use.

However, those who are prescribed marijuana may be benefiting greatly from access to medical marijuana. The same research showed that compared to users who are not medical marijuana patients, young adult medical marijuana patients use more marijuana, and vaporize concentrates of marijuana, such as oil, dab, and wax, more commonly.

On the flip side, many marijuana users who do not access the drug through medical sources report self-medicating untreated symptoms with marijuana and other drugs illegally.

And another study of healthcare providers in the state of Washington, where marijuana is legal for both medical and recreational use, shows that many of them are uncomfortable recommending medical marijuana.

So while the medical marijuana system does appear to be providing benefit to some, there are issues in terms of not reaching those who would benefit and potentially increasing access to medical marijuana for non-medical purposes.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Pickle K. Big pharma takes on marijuana legalization: the synthetic marijuana vs. botanical marijuana paradox. 2018. 5 Emory Corp. Governance & Accountability Rev. Perspectives 127.

  2. U.S. Department of Health and Human Services. National Center for Complementary and Integrative Health. Cannabis (marijuana) and cannabinoids: what you need to know. Updated November 2019.

  3. Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disordersJ Thorac Dis. 2017;9(7):2079-2092. doi:10.21037/jtd.2017.06.104

  4. Badowski S, Smith G. Cannabis use during pregnancy and postpartumCan Fam Physician. 2020;66(2):98-103.

  5. Madras BK. Update of cannabis and its medical use. World Health Organization. 37th ECDD (2015).

  6. Thompson R, DeJong K, Lo J. Marijuana use in pregnancy: a reviewObstet Gynecol Surv. 2019;74(7):415-428. doi:10.1097/OGX.0000000000000685

  7. Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learnNeuropsychopharmacology. 2015;40(1):61-87. doi:10.1038/npp.2014.147

  8. Goldschmidt L, Richardson GA, Willford JA, Severtson SG, Day NL. School achievement in 14-year-old youths prenatally exposed to marijuanaNeurotoxicol Teratol. 2012;34(1):161-167. doi:10.1016/j.ntt.2011.08.009

  9. Day NL, Leech SL, Goldschmidt L. The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioningNeurotoxicol Teratol. 2011;33(1):129-136. doi:10.1016/j.ntt.2010.07.006

  10. Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brainFuture Neurol. 2011;6(4):459-480. doi:10.2217/fnl.11.27

  11. LaFrance EM, Stueber A, Glodosky NC, Mauzay D, Cuttler C. Overbaked: assessing and predicting acute adverse reactions to cannabis. Journal of Cannabis Research. 2020 Dec;2(1):1-0. doi:10.1186/s42238-019-0013-x

  12. American Academy of Allergy, Asthma, and Immunology. Marijuana cannabis allergy. Updated Sept. 28, 2020.

  13. U.S. Food and Drug Administration. Marinol (dronabinol): Highlights of prescribing information. Updated Aug. 2017.

  14. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care settingP T. 2017;42(3):180-188.

  15. Lankenau S, Fedorova E, Reed M, Schrager S, Iverson E, Wong C. Marijuana practices and patterns of use among young adult medical marijuana patients and non-patient marijuana users. Drug and Alcohol Dependence, 170, 181–188. 2017. doi:10.1016/j.drugalcdep.2016.10.025

  16. Carlini BH, Garrett SB, Carter GT. Medicinal cannabis: a survey among health care providers in Washington stateAm J Hosp Palliat Care. 2017;34(1):85-91. doi:10.1177/1049909115604669

Additional Reading
  • Gieringer D, Rosenthal E, Carter G. Marijuana Medical Handbook: Practical Guide to Therapeutic Uses of Marijuana. Quick American Archives. 2008.